

Scales to measure HSP in children before adolescence

Endorsed by ERN-RND: 11/02/2018

Introduction to the European Reference Network for Rare Neurological Diseases (ERN-RND):

ERN-RND is a European Reference Network established and approved by the European Union. ERN-RND is a healthcare infrastructure which focuses on rare neurological diseases (RND). The three main pillars of ERN-RND are (i) network of experts and expertise centres, (ii) generation, pooling and dissemination of RND knowledge, and (iii) implementation of e-health to allow the expertise to travel instead of patients and families.

ERN-RND unites 32 of Europe's leading expert centres in 13 Member States and includes highly active patient organizations. Centres are located in Belgium, Bulgaria, Czech Republic, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, Slovenia, Spain and the UK.

The following disease groups are covered by ERN-RND:

- Ataxias and Hereditary Spastic Paraplegias
- Atypical Parkinsonism and genetic Parkinson's Disease
- Dystonia, Paroxysmal Disorder and Neurodegeneration with Brain Ion Accumulation
- Frontotemporal Dementia
- Huntingtons' Disease and other Choreas
- Leukodystrophies

Specific information about the network, the expert centres and the diseases covered can be found at the networks web site www.ern-rnd.eu.

Recommendation for clinical use:

The European Reference Network for Rare Neurological Diseases strongly recommends the use of the Spastic Paraplegia Rating Scale (SPRS) as best clinical practice for the assessment and rating of patients with Spastic Paraplegia.



Disclaimer:

Clinical practice guidelines, practice advisories, systematic reviews and other guidance published, endorsed or affirmed by ERN-RND are assessments of current scientific and clinical information provided as an educational service. The information (1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; (2) is not continually updated and may not reflect the most recent evidence (new information may emerge between the time information is developed and when it is published or read); (3) addresses only the question(s) specifically identified; (4) does not mandate any particular course of medical care; and (5) is not intended to substitute for the independent professional judgement of the treating provider, as the information does account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ERN-RND provided this information on an "as is" basis, and makes no warranty, expressed or implied, regarding the information. ERN-RND specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ERN-RND assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

METHODOLOGY

The endorsement process has been performed by the Disease group for Ataxia and Hereditary Spastic Paraplegias of ERN-RND.

Disease group for Ataxia and Hereditary Spastic Paraplegias:

Disease group coordinators:

Caterina Mariotti^{16;} Rebecca Schuele-Freyer¹⁴

Disease group members:

Healthcare professionals:

Segolene Ayme¹; Enrico Bertini²; Kristl Claeys³; Maria Teresa Dotti⁴; Alexandra Durr¹; Antonio Federico⁴; Josep Gámez⁵; Paola Giunti⁶; David Gómez-Andrés⁵; Kinga Hadziev⁷; York Hellenbroich⁸; Jaroslav Jerabek⁹; Mary Kearney¹⁰; Jiri Klempir¹¹; Thomas Klockgether¹²; Thomas Klopstock¹³; Norbert Kovacs⁷; Ingeborg Krägeloh-Mann¹⁴; Berry Kremer¹⁵; Alfons Macaya⁵; Bela Melegh⁷; Maria Judit Molnar⁸; Isabella Moroni¹⁶; Alexander Münchau⁸; Esteban Muñoz¹⁷; Lorenzo Nanetti¹⁶; Andrés Nascimento¹⁷; Mar O'Callaghan¹⁷; Damjan



Osredkar¹⁸; Massimo Pandolfo¹⁹; Joanna Pera²⁰; Borut Peterlin¹⁸; Maria Salvadó⁵; Ludger Schöls¹⁴; Deborah Sival¹⁵; Matthis Synofzik¹⁴; Franco Taroni¹⁶; Sinem Tunc⁸; Bart van de Warrenburg²¹; Judith van Gaalen²¹; Martin Vyhnálek⁹; Michèl Willemsen²¹; Ginevra Zanni²; Judith Zima⁷; Alena Zumrová⁹

Patient representatives:

Lori Renna Linton¹⁰, Cathalijne van Doorne¹⁰

Endorsement process:

- Mapping of used disease scales by disease group June November 2018
- Proposal for endorsement of rating scale by ERN-RND disease group coordinators November 2018
- Discussion in ERN-RND disease group 11/02/2019
- Consent on endorsement of disease scale 11/02/2019



¹ Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salepétrière, France: Reference Centre for Rare Diseases 'Neurogenetics'; ² Pediatric hospital Bambino Gesù, Rome, Italy; ³ University Hospitals Leuven, Belgium; ⁴ AOU Siena, Italy; ⁵ Hospital Universitari Vall d'Hebron, Spain; ⁶ University College London Hospitals NHS Foundation Trust, United Kingdom; ⁷ University of Pécs, Hungary; ⁸ Semmelweis University, Hungary; ⁸ Universitätsklinikum Schleswig-Holstein, Germany; ⁹ Motol University Hospital, Czech Republic; ¹⁰ Patient representative; ¹¹ General University Hospital in Prague, Czech Republic; ¹² Universitätsklinikum Bonn, Germany; ¹³ Klinikum der Universität München, Germany; ¹⁴ Universitätsklinikum Tübingen, Germany; ¹⁵ University Medical Center Groningen, Netherlands; ¹⁶ Foundation IRCCS neurological institute Carlo Besta – Milan, Italy; ¹⁷ Hospital Clínic i Provincial de Barcelona y Hospital de Sant Joan de Déu, Spain; ¹⁸ University Medical Centre Ljubljana, Slovenia; ¹⁹ Université libre de Bruxelles, Belgium; ²⁰ University Hospital in Krakow, Poland; ²¹ Stichting Katholieke Universiteit, doing business as Radboud University Medical Center Nijmegen, Netherlands;

Recommended scales:

Domain	Scale
Gross motor abilities	GMFCS – Gross Motor Classification System, Palisano et al. 1997, Dev Med Chil Neurol 39:214-23 CanChild: www.canchild.ca Illustrations Version 2 © Bill Reid, Kate Willoughby, Adrienne Harvey and Kerr Graham, The Royal Children's Hospital Melbourne ERC151050
Fine motor abilities	MACS – Manual Ability Classification System For children <4 years: Mini MACS, Ann- Christin Eliasson, Lena Krumlinde-Sundholm, 2013 Contributors: Ann-Marie Öhrwall, Ulla Wahlström, Åsa Persson-Annerste
Language and communication	Viking Speech Scale, Lindsay Pennington, Tone Mjøen, Maria da Graça Andrada, Janice Murray, Viking Speech Scale, 2010©, Copyright © Newcastle University UK, Vestfold Hospital Trust Norway, Centro de Reabilitação de Paralisia Cerebral Calouste Gulbenkian- Lisbon and Manchester Metropolitan University UK, 2011. 2010
Eating and drinking	EDACS - Eating and Drinking Ability Classification System, Sellers D, Mandy A, Pennington L, Hankins M, Morris C. Development and reliability of a system to classify the eating and drinking ability of people with cerebral palsy. Developmental medicine and child neurology 2014;56:245- 51.
Learning disability	Apply scale used in daily routine, consider motor involvement.
Urological issues	Dysfunctional voiding and incontinence symptoms score questionnaire, Akbal C, Genc Y, Burgu B, Ozden E, Tekgul S. Dysfunctional voiding and incontinence scoring system: quantitative evaluation of incontinence symptoms in pediatric population. The Journal of urology 2005;173:969-73.



References

Wood E, Rosenbaum P. The gross motor function classification system for cerebral palsy: a study of reliability and stability over time. Developmental medicine and child neurology 2000;42:292-6.

Towns M, Rosenbaum P, Palisano R, Wright FV. Should the Gross Motor Function Classification System be used for children who do not have cerebral palsy? Developmental medicine and child neurology 2018;60:147-54.

Eliasson AC, Krumlinde-Sundholm L, Rosblad B, et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Developmental medicine and child neurology 2006;48:549-54.

Eliasson AC, Ullenhag A, Wahlstrom U, Krumlinde-Sundholm L. Mini-MACS: development of the Manual Ability Classification System for children younger than 4 years of age with signs of cerebral palsy. Developmental medicine and child neurology 2017;59:72-8.

Pennington L, Virella D, Mjoen T, et al. Development of The Viking Speech Scale to classify the speech of children with cerebral palsy. Research in developmental disabilities 2013;34:3202-10.

Sellers D, Mandy A, Pennington L, Hankins M, Morris C. Development and reliability of a system to classify the eating and drinking ability of people with cerebral palsy. Developmental medicine and child neurology 2014;56:245-51.

Benfer KA, Weir KA, Bell KL, Ware RS, Davies PSW, Boyd RN. The Eating and Drinking Ability Classification System in a population-based sample of preschool children with cerebral palsy. Developmental medicine and child neurology 2017;59:647-54.

Akbal C, Genc Y, Burgu B, Ozden E, Tekgul S. Dysfunctional voiding and incontinence scoring system: quantitative evaluation of incontinence symptoms in pediatric population. The Journal of urology 2005;173:969-7

